




# SCC Coaching Call

### Cole Stanley, MD, CCFP

### Medical Lead, Provincial BOOST Collaborative

May 30, 2019

🍠 #BOOSTqi @bccfe @ccsmd











MSPQI



### Disclosures

### **Dr. Stanley**

- Travel grants received for conference attendance from the following
  - 2017 Gilead Sciences
  - 2016 Canadian Association for HIV Research (with support from Viiv), Gilead Sciences
- Advisory Board Viiv Canada, March 2019
- Mitigating bias
  - No discussion of specific HIV or Hep C therapy in this talk

# List of topics we can cover

- 1) Forming your QI team
- 2) Getting a QI coach
- 3) Meeting regularly
- 4) Developing aims
- 5) Measuring
- 6) Testing changes
- 7) Barriers you are encountering
- 8) Tips for other teams





- Withdrawal suppression
- Decreased illicit opioid (and cocaine) use
- Reduced risk of HCV/HIV
- Better HIV control

# **Opioid agonist therapy**


Decreased criminal justice system involvement
Significantly reduced mortality (both all-cause and substance-related)

Retention on methadone and buprenorphine is associated with substantial reductions in the rate of all cause and overdose mortality



### B.C. Coroner's data...

### Top Relevant Drugs Detected Among Illicit Drug Overdose Deaths, 2016-2017




Suboxone saved Sabrina?

N 8	
	Meds Care

### Majority started on OAT, minority retained on therapy for adequate period

70,000



### SUBSTANCE USE TREATMENT **JOURNEY MAP** what do peers experience?

"I told counsellors what they wanted to hear to

"There's a lot of trust [in the healthcare system]

"You need to be honest, open, willing before

"I don't believe help actually exists"

avoid being forced into treatment\*

that's been broken"

seeking treatment"

WHY I LOOK FOR

Friends dving

treatment

you to quit

Overdose

like HIV/HCV

FEAR - of overdose

MCFD, court system,

employer mandating

Loved ones ask

Other health issues

TREATMENT





It can be hard to leave this area because:

Need to be in withdrawal or already "clean" before treatment - and once you're in, you lose your autonomy

FEAR - of losing freedom, autonomy, privacy, friends and medication like benzos

Treatment means abandoning commitments to pets, work or family

Hard to work while in treatment; you can't claim addiction as a disability. Rent still needs to be paid

CONFUSION - There is a long wait for services - and it's confusing to know which ones to access

Don't want to feel the negative emotions that substances cover up

Peer pressure to keep using

HOPELESSNESS

Complementary ENTRY POINTS therapies

> Hospital 'Psych ward'

Emergency Department

Peer

Residential

Family doctor

care

Team-based

care

Detox


networks

services

Mental health

Walk-in

clinics



These help me stay here: Peer support networks Counselling Church Holistic approaches Gender/cultural needs met Social media 12 step groups Well educated, informed providers punitive - worse than when Getting my life back Being treated with respect/dignity transitions between BRITISH COLUMBIA


PATIENT SAFETY

QUALITY COUNCIL

therapies'


RECOVERY

https://bcpsqc.ca /documents/201 7/12/Journey-Mapping-Substance-Use-Treatment-Report.pdf



### 40 follow-up documented






### Discontinuation rate is highest during first few months of therapy

J Addict Med, 2015; 9(6): 440 -446

- Standardize clinical data entry
- Regular client feedback surveys
- Reminder calls for appointments
- Reminder calls for expiring prescriptions
- > Assertive outreach for clients lost to care
- Follow-up on missed oOAT dose faxes from pharmacies
- > Work-flow changes to support Suboxone inductions





# Testing Changes – PDSA Cycles

PLAN

**STUDY** 

What will happen if we try something different? What question do we want to ask & what is our prediction? Who will carry this out? (When? How? Where?)

#### DO

Let's try it! Carry out your plan Document any problems Begin data analysis


#### Did it work? Complete data analysis Compare results to your prediction Summarize your results

#### ACT

What's next? Ready to implement/adapt? Try something else/abandon? Next cycle?

### Collaborative Aims


- 95% of clients have an active OAT prescription
- 95% of those clients with an active OAT prescription will be retained on therapy for greater than 3 months
- 100% of teams have a process to monitor and incorporate the patient voice



# Team Aims

To align with Collaborative aims





BMJ Quality & Safety Latest content Current iss						
Hom	e / Archive /	Volume 28, Issue 5				
	Article Text	Original research Evolving quality improvement support strategies to improve Plan—	PDF			
	Article info	Do-Study-Act cycle fidelity: a retrospective mixed-methods study a Chris McNicholas <sup>1, 2</sup> , Laura Lennox <sup>1</sup> , Thomas Woodcock <sup>1</sup> , Derek Bell <sup>1</sup> , Julie E Reed <sup>1</sup>				


Principle	Measure		
Documentation	All PDSA cycle stages documented	Iterative cycles	PDSA cycle within iterative series of 2 or more cycles
	'Study' section documented in past tense	Small-scale testing	PDSA iterative series increasing testing scale
Learning activity	Learning activity present in PDSA		
	cycle	Use of data over time	PDSA iterative series using regular data over time
Prediction	Explicit prediction documented in PDSA cycle		

### **Project Progress Assessment Scale**

- 0.5 Intent to Participate
- 1.0 Charter and team established
- 1.5 Planning for the project has begun
- 2.0 Activity, but no changes
- 2.5 Changes tested, but no improvement
- 3.0 Modest improvement
- 3.5 Improvement
- 4.0 Significant improvement
- 4.5 Sustainable improvement
- 5.0 Outstanding sustainable results


# Who are we measuring?







- 1 our clients with OUD
- 2 we are primary OAT provider
- 3 have active OAT rx
- 4 retained on OAT >3mos





## https://pollev.com/ranag760

LLL

LILL

I KI KI KI

~ LL

DEDE

10 LL

m L

~ LL

- 6

DEL



# 304.0 opioid use disorder



### DSM-5 CLINICAL DIAGNOSTIC CRITERIA FOR OPIOID USE DISORDER<sup>1</sup>



# MRP – Dr. Cole Stanley






# **POS – John Ruedy Clinic**








# Start small












	А	В	С	D	Е	F	G
1	Patient ID	OAT	dose	Start	End	MRSD	MRP
2	1	methadone	50	15-Jan	02-Feb	01-Jan-17	Dr X
3	2	Suboxone	24	28-Jan	07-Feb	15-Jan-19	Dr Y
4	3	Kadian	400	15-Jan	27-Jan	28-Dec-18	Dr Y
5	4	none					Dr Z
6	5	methadone	100	05-Jan	31-Jan	12-Oct-18	Dr X



12	$\frac{1}{2}$ $\times$ $f_x$ =-DAYS(G2, A2)									
	Α	В	С	D	E	F	G	Н	I	
1	Date	Patient ID	OAT	dose	Start	End	MRSD	MRP	<b>Retention (days)</b>	
2	15-Jan	1	methadone	50	15-Jan	02-Feb	01-Jan-17	Dr X	744	
3	27-Jan	2	Suboxone	24	28-Jan	07-Feb	15-Jan-19	Dr Y	12	
4	15-Jan	3	Kadian	400	15-Jan	27-Jan	28-Dec-18	Dr Y	18	
5	16-Jan	4	none					Dr Z		
6	05-Jan	5	methadone	100	05-Jan	31-Jan	12-Oct-18	Dr X	85	
4 5	15-Jan 16-Jan	3 4	Kadian none	400	15-Jan	27-Jan	28-Dec-18	Dr Y Dr Z		

## Today is Jan 31, 2019

	Α	В	С	D	E	F	G	Н	I
1	Date	Patient ID	OAT	dose	Start	End	MRSD	MRP	Retention (days)
2	15-Jan	1	methadone	50	15-Jan	02-Feb	01-Jan-17	Dr X	744
3	27-Jan	2	2 Suboxone	24	28-Jan	07-Feb	15-Jan-19	Dr Y	12
4	15-Jan	3	8 Kadian	400	15-Jan	27-Jan	28-Dec-18	Dr Y	18
5	16-Jan	4	l none					Dr Z	
6	05-Jan	5	methadone	100	05-Jan	31-Jan	12-Oct-18	Dr X	85

	А	В	С	D	Е	F	G	Н	1
1	Date	Patient ID	OAT	dose	Start	End	MRSD	MRP	<b>Retention (days)</b>
2	15-Jan	1	methadone	50	15-Jan	02-Feb	01-Jan-17	Dr X	744
3	27-Jan	2	Suboxone	24	28-Jan	07-Feb	15-Jan-19	Dr Y	12
4	15-Jan	3	Kadian	400	15-Jan	27-Jan	28-Dec-18	Dr Y	18
5	16-Jan	4	none					Dr Z	
6	05-Jan	5	methadone	100	05-Jan	31-Jan	12-Oct-18	Dr X	85

